Paydirt
YX
Insider

Yu Xia

Director

Yu Xia (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Summit Therapeutics Inc. (SMMT). Across 1 priced purchase filing, the average 21-session return was -15.9% from execution and -13.7% from disclosure (delay-adjusted; derived). The largest single filing was $10.0M of SMMT (533,617 sh × $18.74, as filed), executed Oct 21 2025.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
-15.9%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-13.7%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$10.0M
shares × price, as filed
Last traded
Oct 21 2025
Filed Oct 23 2025

Median ADV $66.4M across their filed names

Open performance
Volume by month
$10.0M$5.0M$0Oct 2024Apr 2025Oct 2025Apr 2026Oct 2025 · buys $10.0M
Buys $10.0M Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 1 filing

Sector per market data · by filing · past 12 months

Most traded names
SMMT Summit Therapeutics Inc. SMMT · 1 buy · 0 sells 1 filing
Recent filings
SMMTPURCHASE Summit Therapeutics Inc. View filing → $10.0M
533,617 sh × $18.74
Exec Oct 21 2025
Filed Oct 23 2025 · 9:06 PM ET